NCT07787182 · Phase 1 · RECRUITING
A Study of LY4405094 in Healthy Participants and Participants With Alzheimer's Disease
This early trial tests LY4405094, an experimental drug from Eli Lilly, in healthy volunteers and people with Alzheimer's. Researchers are measuring safety, how much of the drug reaches the bloodstream and brain fluid, and levels of an Alzheimer's-related brain protein. It is a Phase 1 trial, meaning a first look at safety, not proof it works.
You may qualify if
- Participants must meet eligibility criteria in the ATMP screening protocol before entry into the treatment study.
You're excluded if
- Have known allergies to LY4405094, related compounds (including remternetug), or any components of the formulation, including LY4405094.
- Have known allergic reactions to adhesive or hydrogels or a family history of adhesive skin allergies.
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2026-10-22